☆ 4.7 Review

Clinical and Translational Applications of Serological and Histopathological Biomarkers in Metastatic Breast Cancer: A Comprehensive Review

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Review Medicine, Research & Experimental

Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets

Jie Xia et al.

Summary: The family of aldehyde dehydrogenases (ALDHs) plays important roles in cellular and tissue homeostasis through the oxidation of aldehydes to carboxylic acids. Dysregulation of ALDHs is associated with various diseases, especially solid tumors, where they maintain stem-cell-like characteristics and contribute to rapid clinical progressions. ALDHs have potential as biomarkers for disease diagnosis and prognosis, but further clinical studies are needed for broad application.

MEDCOMM (2023)

Add to Collection

Article Oncology

The non-fatal burden of cancer in Belgium, 2004-2019: a nationwide registry-based study

Vanessa Gorasso et al.

Summary: The non-fatal burden of cancer in Belgium increased from 2004 to 2019, with breast cancer and prostate cancer having the highest morbidity impact. Skin cancer showed a significant increase in burden for both sexes during this period.

BMC CANCER (2022)

Add to Collection

Review Genetics & Heredity

Clinical utility of liquid biopsy in breast cancer: A systematic review

Galo Duque et al.

Summary: This systematic review focuses on the clinical utility of liquid biopsy in patients with breast cancer, indicating its importance for diagnosis, treatment and follow-up in this context. The clinical applications of liquid biopsy in breast cancer are found to be clinically significant, although there is heterogeneity in the publications.

CLINICAL GENETICS (2022)

Add to Collection

Review Oncology

Role of ctDNA in Breast Cancer

Marta Sant et al.

Summary: Circulating tumor DNA (ctDNA) plays an important role in breast cancer research and clinical practice, allowing for screening, diagnosis, treatment selection, and prognosis assessment. Analysis of ctDNA provides a more accurate understanding of the heterogeneity of breast cancer, enabling monitoring of disease progression and resistance mutations. With the application of new bioinformatics tools, the use of ctDNA in breast cancer will become more frequent, enhancing our knowledge of tumor biology.

CANCERS (2022)

Add to Collection

Article Oncology

Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study

Jannes Heylen et al.

Summary: This study examines the relationship between elevated baseline serum CA 15.3 (>30 kU/L) and the prevalence of primary or secondary metastatic disease in breast cancer. The results show that patients with higher baseline CA 15.3 levels have a higher risk of both primary and secondary metastatic disease.

CLINICAL BREAST CANCER (2022)

Add to Collection

Review Oncology

Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)

Beata Smolarz et al.

Summary: Breast cancer is the most commonly diagnosed malignant tumor in women worldwide, with treatment strategies varying based on molecular subtypes. Triple negative breast cancer presents a therapeutic challenge, and future concepts aim to individualize therapy for improved outcomes.

CANCERS (2022)

Add to Collection

Review Oncology

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival

F. Miglietta et al.

Summary: In recent years, there have been significant advancements in the treatment of metastatic breast cancer, leading to an increase in the length of progression-free survival and overall survival. This review comprehensively describes the most important progress in the therapeutic approaches for different subtypes of breast cancer.

ESMO OPEN (2022)

Add to Collection

Article Medicine, General & Internal

Inclusion of the US Preventive Services Task Force Recommendation for Mammography in State Comprehensive Cancer Control Plans in the US

Mehrnoosh Soori et al.

Summary: State comprehensive cancer control plans for mammography screening in women at average risk for breast cancer are not consistent with USPSTF recommendations, partly due to variations in state-specific planning considerations and discretion, as well as differences in recommendations among national organizations.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Biochemistry & Molecular Biology

An Eleven-microRNA Signature Related to Tumor-Associated Macrophages Predicts Prognosis of Breast Cancer

Sharmilla Devi Jayasingam et al.

Summary: This study explores the relationship between tumor-associated macrophages and miRNAs, constructing a novel TRM signature with potential prognostic factors in breast cancer patients, revealing the importance of these signatures in prognostic assessment and immune-related pathways.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

J. Cortes et al.

Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article

Diagnostic impact of CEA and CA 15-3 on monitoring chemotherapy of breast cancer patients

Diya Hasan

Journal of Circulating Biomarkers (2022)

Add to Collection

Article Oncology

Breast Cancer Statistics, 2022

Angela N. Giaquinto et al.

Summary: This article provides an update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and mammography screening. It shows that breast cancer incidence rates have increased over the past few decades, driven by localized-stage and hormone receptor-positive disease. However, breast cancer mortality rates have been steadily declining since 1989, although at a slower pace in recent years. Despite lower incidence rates, there remains a racial disparity in breast cancer mortality, with higher rates among Black women compared to White women.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Review Oncology

Liquid biopsy: current technology and clinical applications

Mina Nikanjam et al.

Summary: Liquid biopsies, including circulating extracellular nucleic acids (cfDNA and ctDNA) and circulating tumor cells (CTCs), have important clinical applications in precision oncology, such as predicting treatment response and resistance, analyzing prognosis and tumor burden, and detecting cancer at early stages. This review provides an overview of current technologies and clinical applications for liquid biopsies, highlighting the potential of this powerful tool in multiple aspects of cancer management.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Oncology

Current and future burden of breast cancer: Global statistics for 2020 and 2040

Melina Arnold et al.

Summary: Breast cancer is the most commonly diagnosed cancer worldwide, with over 2.3 million new cases and 685,000 deaths in 2020. There is significant geographic variation in incidence rates, with lower rates in some Asian and African countries and higher rates in countries like Australia, New Zealand, Northern America, and parts of Europe. Mortality rates show less variation, but transitioning countries still bear a disproportionate burden of breast cancer deaths. By 2040, the burden of breast cancer is predicted to increase further due to population growth and ageing. Global efforts are needed to address this growing burden, especially in transitioning countries where incidence rates are rising rapidly and mortality rates remain high.

BREAST (2022)

Add to Collection

Review Oncology

Androgen receptor function and targeted therapeutics across breast cancer subtypes

Emily A. Kolyvas et al.

Summary: Breast cancer is a common and deadly cancer, and the role of AR in this type of cancer is still not fully understood. However, targeting AR in breast cancer may have therapeutic potential and further research is needed for effective treatment.

BREAST CANCER RESEARCH (2022)

Add to Collection

Review Medical Laboratory Technology

Liquid Biopsy in Breast Cancer

Timothy Kwang Yong Tay et al.

Summary: Liquid biopsies have shown promising results in breast cancer, particularly in monitoring treatment response and predicting disease progression or relapse. With further research and advancements in technology, liquid biopsies may have a greater role in the breast cancer clinic in the future.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2021)

Add to Collection

Editorial Material Oncology

Estrogen Receptor: A Paradigm for Targeted Therapy

Senthil Damodaran et al.

Summary: The majority of breast cancers overexpress estrogen receptors, making endocrine therapy essential in treatment, and estrogen receptor targeting has proven to significantly impact patient survival. Knight and colleagues' landmark article in 1977 laid the foundation for the importance of estrogen receptors in treatment, playing a key role in breast cancer therapy.

CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Clinical utility of circulating tumor cells: an update

Antoine Vasseur et al.

Summary: The prognostic role of circulating tumor cells (CTCs) has been well established in various types of cancer, but their definitive role in diagnostic and treatment strategies is still to be defined. Current clinical research on CTCs focuses mainly on breast, lung, colorectal, and prostate cancer. Studies are primarily exploring treatment approaches based on CTC count or variations, as well as treatment based on the molecular characteristics of CTCs.

MOLECULAR ONCOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Advanced Approaches to Breast Cancer Classification and Diagnosis

M. Zubair et al.

Summary: Breast cancer is highly heterogeneous, requiring early and advanced molecular diagnostic tools for accurate detection. Currently, only a few biomarkers have been approved by the FDA for assessing breast cancer. Advanced technologies such as portable biosensors hold promise for providing more precise diagnostics and guiding specific treatment methods.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Oncology

Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer

Molly A. Nelson et al.

Summary: Increased levels of total tumor-infiltrating lymphocytes (TILs) are associated with good prognosis in several breast cancer subtypes; different subtypes of TILs impact both tumor cells and immune cells in various ways; specific CD8(+) T cells and NK cells are associated with better clinical outcomes; therapeutic strategies include PD-1/PD-L1 blockade, CAR T cell therapy, and ex vivo-stimulated NK cells.

CANCER AND METASTASIS REVIEWS (2021)

Add to Collection

Article Oncology

High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer

Li Chen et al.

Summary: High miR-223 expression is associated with improved disease-free survival and overall survival in breast cancer patients, especially those with the triple-negative breast cancer subtype. MiR-223 serves as a valid and independent prognostic biomarker in breast cancer.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Nicola Fusco et al.

Summary: Despite advances in diagnosis and treatment of metastatic breast cancer (MBC), it remains largely incurable. Pharmacologic targeting of PIK3CA in HR+/HER2(-) MBC has shown significant benefits, and tailored patient selection is crucial for optimal outcomes. Clinical relevant PIK3CA alterations can be detected in various biospecimens using different techniques, guiding appropriate clinical management.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Gizem Oner et al.

Summary: Studies on PD-L1 expression in breast cancer, especially in TNBC, have gained importance in recent years. Our research found that high PD-L1 expression in TCs is associated with better outcomes, and PD-L1 positivity in ICs may correlate with better response to chemotherapy in TNBC patients.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3

L. De Cock et al.

Summary: CA 15.3 elevation in follow-up of early breast cancer patients can lead to the timely diagnosis of metastatic disease in 37% of patients, resulting in significantly longer overall survival compared to other triggering factors.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

Pamela J. Goodwin et al.

Summary: The study showed that metformin significantly reduces CA 15-3 levels in early-stage breast cancer patients. This reduction is independent of tumor characteristics and treatment methods.

JNCI CANCER SPECTRUM (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Circulating tumor cells: biology and clinical significance

Danfeng Lin et al.

Summary: CTCs, tumor cells that have sloughed off the primary tumor and circulate in the blood, have potential for identifying targets against cancer metastasis. Detecting these rare CTCs in the massive pool of blood cells is challenging, but emerging detection technologies have deepened our understanding of their biology and clinical applications. Molecular markers, such as epithelial cell adhesion molecule, play a key role in CTC detection, with properties like epithelial-to-mesenchymal transition and stemness indicating increased metastatic capacity.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Oncology

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

Jamie O. Brett et al.

Summary: ESR1 mutations play a crucial role in breast cancer treatment, affecting tumor sensitivity to therapies. These mutations influence resistance in estrogen receptor-targeting and combination therapies, requiring further research for better understanding and treatment strategies.

BREAST CANCER RESEARCH (2021)

Add to Collection

Article Oncology

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer J. Gao et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Genetics & Heredity

Tracking cancer progression: from circulating tumor cells to metastasis

Francesc Castro-Giner et al.

GENOME MEDICINE (2020)

Add to Collection

Review Cell Biology

A review on methods for diagnosis of breast cancer cells and tissues

Ziyu He et al.

CELL PROLIFERATION (2020)

Add to Collection

Article Oncology

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Substance Abuse

ALCOHOL'S EFFECTS ON BREAST CANCER IN WOMEN

Jo L. Freudenheim

ALCOHOL RESEARCH-CURRENT REVIEWS (2020)

Add to Collection

Article Medicine, General & Internal

Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases

Yana Vinogradova et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Oncology

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing

Nan Wang et al.

CHINESE JOURNAL OF CANCER RESEARCH (2020)

Add to Collection

Review Oncology

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

R. Condorelli et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Breast Cancer Treatment A Review

Adrienne G. Waks et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Review Oncology

Immunotherapy and targeted therapy combinations in metastatic breast cancer

Francisco J. Esteva et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

Fabrice Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Public, Environmental & Occupational Health

Estimates of past and future time trends in age-specific breast cancer incidence among women in Karachi, Pakistan: 2004-2025

Sidra Zaheer et al.

BMC PUBLIC HEALTH (2019)

Add to Collection

Review Oncology

ESR1 mutations in breast cancer

Derek Dustin et al.

CANCER (2019)

Add to Collection

Review Oncology

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging-A Literature Review

Gabrielle Planes-Laine et al.

CANCERS (2019)

Add to Collection

Review Medicine, Research & Experimental

Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer

Vilem Maly et al.

IN VIVO (2019)

Add to Collection

Article Oncology

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer

Sheau W. Lok et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Oncology

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98

Kevin H. Kensler et al.

BREAST CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Burden of early, advanced and metastatic breast cancer in The Netherlands

G. T. Vondeling et al.

BMC CANCER (2018)

Add to Collection

Article Pathology

A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer

Xu Chen et al.

HUMAN PATHOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Jennifer K. Litton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Medicine, Research & Experimental

Alcohol dehydrogenase and aldehyde dehydrogenase in malignant neoplasms

Karolina Orywal et al.

CLINICAL AND EXPERIMENTAL MEDICINE (2017)

Add to Collection

Article Oncology

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Ian E. Krop et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Chemistry, Analytical

Early Diagnosis of Breast Cancer

Lulu Wang

SENSORS (2017)

Add to Collection

Article Oncology

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

Fergus J. Couch et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations

Su Min Ha et al.

AMERICAN JOURNAL OF ROENTGENOLOGY (2017)

Add to Collection

Article Oncology

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

Anna Kazarian et al.

BRITISH JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial

Philip Hepp et al.

ANTICANCER RESEARCH (2016)

Add to Collection

Article Oncology

BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer

Yong Hwa Eom et al.

JOURNAL OF BREAST CANCER (2016)

Add to Collection

Review Oncology

Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities

Sao Jiralerspong et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Review Oncology

Circulating tumor cells in breast cancer

Francois-Clement Bidard et al.

MOLECULAR ONCOLOGY (2016)

Add to Collection

Review Biochemistry & Molecular Biology

The role of MicroRNAs in human cancer

Yong Peng et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)

Add to Collection

Article Oncology

Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets

David W. Clark et al.

ANNALS OF TRANSLATIONAL MEDICINE (2016)

Add to Collection

Review Oncology

Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring

Andrew McGuire et al.

CANCER AND METASTASIS REVIEWS (2015)

Add to Collection

Article Medicine, General & Internal

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Obstetrics & Gynecology

Breast cancer risk factors

Marzena Kaminska et al.

MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY (2015)

Add to Collection

Review Oncology

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

R. Salgado et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel

Nadine Tung et al.

CANCER (2015)

Add to Collection

Article Oncology

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

Eduardo Martinez de Duenas et al.

BREAST CANCER RESEARCH AND TREATMENT (2014)

Add to Collection

Article Oncology

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers

Pierluigi Gasparini et al.

ONCOTARGET (2014)

Add to Collection

Article Oncology

Biological subtypes of breast cancer: Prognostic and therapeutic implications

Ozlem Yersal et al.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Medical Laboratory Technology

Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression

Corinna Eichelser et al.

CLINICAL CHEMISTRY (2013)

Add to Collection

Article Multidisciplinary Sciences

Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer

Luciano Cascione et al.

PLOS ONE (2013)

Add to Collection

Article Oncology

Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients

Heidi Schwarzenbach et al.

BREAST CANCER RESEARCH AND TREATMENT (2012)

Add to Collection

Review Oncology

Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies

Eitan Amir et al.

CANCER TREATMENT REVIEWS (2012)

Add to Collection

Review Oncology

Next-generation sequencing in breast cancer: first take home messages

Christine Desmedt et al.

CURRENT OPINION IN ONCOLOGY (2012)

Add to Collection

Article Medicine, Research & Experimental

Serum Overexpression of MicroRNA-10b in Patients with Bone Metastatic Primary Breast Cancer

F-L Zhao et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)

Add to Collection

Article Multidisciplinary Sciences

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Christina Curtis et al.

NATURE (2012)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medical Laboratory Technology

Direct Serum Assay for MicroRNA-21 Concentrations in Early and Advanced Breast Cancer

Sota Asaga et al.

CLINICAL CHEMISTRY (2011)

Add to Collection

Review Oncology

Prognosis of BRCA-associated breast cancer: a summary of evidence

L. Bordeleau et al.

BREAST CANCER RESEARCH AND TREATMENT (2010)

Add to Collection

Review Oncology

BRCA mutations in the management of breast cancer: the state of the art

Steven A. Narod

NATURE REVIEWS CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004

Carol A. Parise et al.

BREAST JOURNAL (2009)

Add to Collection

Review Oncology

Significance, detection and markers of disseminated breast cancer cells

Marc Lacroix

ENDOCRINE-RELATED CANCER (2006)

Add to Collection

Article Biotechnology & Applied Microbiology

Discovery and validation of breast cancer subtypes

Amy V. Kapp et al.

BMC GENOMICS (2006)

Add to Collection

Article Medicine, Research & Experimental

The activity of class I, II, III and IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in breast cancer

W. Jelski et al.

CLINICAL AND EXPERIMENTAL MEDICINE (2006)

Add to Collection

Review Medical Laboratory Technology

Serum tumor markers in breast cancer: Are they of clinical value?

MJ Duffy

CLINICAL CHEMISTRY (2006)

Add to Collection

Article Medical Laboratory Technology

Activity of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in the sera of patients with breast cancer

Wojciech Jelski et al.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2006)

Add to Collection

Article Medicine, General & Internal

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

M Cristofanilli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Oncology

CA27.29:: a valuable marker for breast cancer management.: A confirmatory multicentric study on 603 cases

M Gion et al.

EUROPEAN JOURNAL OF CANCER (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.